Original articleRates of Retinal Nerve Fiber Layer Thinning in Glaucoma Suspect Eyes
Section snippets
Study Design
Subjects were enrolled from the Diagnostic Innovations in Glaucoma Study and the African Descent and Glaucoma Evaluation Study. The study design has been described in detail previously.32 In brief, participants in these studies were evaluated every 6 months, in which patients underwent extensive predetermined clinical examinations. Inclusion criteria for these studies were open angles, a best-corrected visual acuity of 20/40 or better, a spherical refraction within ±5.0 diopters (D), and
Study Population
Four hundred fifty-four eyes of 294 glaucoma suspects were included. One hundred eighty-three patients (62.2%) were women. Mean age ± standard deviation at baseline was 64.5±11.3 years. Ninety-two subjects (31.3%) were of African descent and 202 subjects (68.7%) were of European descent. At the baseline examination, 239 eyes (52.6%) were categorized as having ocular hypertension. The average number of OCT examinations per eye was 4.6 (range, 2–9), with median follow-up of 2.2 years.
Baseline Factors
Forty eyes
Discussion
In this cohort of glaucoma suspects followed up for a relatively short period (2.2 years), eyes in which VFD developed had an approximately 2.5-times faster rate of RNFLT loss compared with eyes that did not develop VFD. Moreover, a 1-μm/year faster rate of RNFL loss resulted in a 2.05-times higher risk of developing VFD. These results suggest that the rate of RNFL loss measured with SD-OCT may be useful for identifying which glaucoma suspect patients are at the highest risk of developing VFD.
References (61)
- et al.
Primary open-angle glaucoma
Lancet
(2004) - et al.
Longitudinal changes in the visual field and optic disc in glaucoma
Prog Retin Eye Res
(2005) - et al.
Monitoring glaucomatous progression using a novel Heidelberg Retina Tomograph event analysis
Ophthalmology
(2007) - et al.
Retinal nerve fiber layer imaging with spectral-domain optical coherence tomography: patterns of retinal nerve fiber layer progression
Ophthalmology
(2012) - et al.
Rates of neuroretinal rim and peripapillary atrophy area change: a comparative study of glaucoma patients and normal controls
Ophthalmology
(2009) - et al.
Evaluation of retinal nerve fiber layer progression in glaucoma: a prospective analysis with neuroretinal rim and visual field progression
Ophthalmology
(2011) - et al.
Evaluation of retinal nerve fiber layer progression in glaucoma: a comparison between spectral-domain and time-domain optical coherence tomography
Ophthalmology
(2011) - et al.
Incidence and rates of visual field progression after longitudinally measured optic disc change in glaucoma
Ophthalmology
(2009) - et al.
Recent developments in optical coherence tomography for imaging the retina
Prog Retin Eye Res
(2007) - et al.
Evaluation of progressive neuroretinal rim loss as a surrogate end point for development of visual field loss in glaucoma
Ophthalmology
(2014)
Progression detection capability of macular thickness in advanced glaucomatous eyes
Ophthalmology
Retinal nerve fiber layer imaging with spectral-domain optical coherence tomography: a prospective analysis of age-related loss
Ophthalmology
Scanning laser polarimetry to measure the nerve fiber layer of normal and glaucomatous eyes
Am J Ophthalmol
Relationship between age and the thickness of the retinal nerve fiber layer in normal subjects
Jpn J Ophthalmol
The effect of age on the nerve fiber population of the human optic nerve
Am J Ophthalmol
The effect of age on normal human optic nerve fiber number and diameter
Ophthalmology
Ocular Hypertension Treatment Study (OHTS) Group. Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS)
Ophthalmology
Predictors of long-term progression in the Early Manifest Glaucoma Trial
Ophthalmology
Differences in optic disc topography between black and white normal subjects
Ophthalmology
The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma
Arch Ophthalmol
Results of the European Glaucoma Prevention Study
Ophthalmology
Differential light threshold: short- and long-term fluctuation in patients with glaucoma, normal controls, and patients with suspected glaucoma
Arch Ophthalmol
Effect of instructions on conventional automated perimetry
Invest Ophthalmol Vis Sci
Factors that influence standard automated perimetry test results in glaucoma: test reliability, technician experience, time of day, and season
Invest Ophthalmol Vis Sci
Approach for identifying glaucomatous optic nerve progression by scanning laser tomography
Invest Ophthalmol Vis Sci
Optimizing and validating an approach for identifying glaucomatous change in optic nerve topography
Invest Ophthalmol Vis Sci
A new statistical approach for quantifying change in series of retinal and optic nerve head topography images
Invest Ophthalmol Vis Sci
Optical coherence tomography longitudinal evaluation of retinal nerve fiber layer thickness in glaucoma
Arch Ophthalmol
Ability of Stratus OCT to detect progressive retinal nerve fiber layer atrophy in glaucoma
Invest Ophthalmol Vis Sci
Optic disc and visual field progression in ocular hypertensive subjects: detection rates, specificity, and agreement
Invest Ophthalmol Vis Sci
Cited by (0)
Financial Disclosure(s): The author(s) have made the following disclosure(s):
Atsuya Miki: Financial support – Nidek
Felipe A. Medeiros: Financial support – Carl-Zeiss Meditec, Heidelberg Engineering, Topcon, Inc.
Robert N. Weinreb: Financial support – Nidek, Topcon, Zeiss Meditec, Alcon, Allergan, Bausch & Lomb; Nonfinancial support – Heidelberg Engineering; Patent - RGC Index
Jeffrey M. Liebmann: Financial support – Carl Zeiss Meditec, Topcon, Inc., Alcon Laboratories, Allergan, Inc, Diopsys Corporation, Glaukos Corporation, Heidelberg Engineering, Merz Pharmaceutical, Inc, Optovue, Inc, Quark Pharmaceuticals, Inc, SOLX, Inc.
Christopher A. Girkin: Financial support – Carl Zeiss Meditech, Inc, Heidelberg Engineering.
Linda M. Zangwill: Nonfinancial support – Heidelberg Engineering, Carl Zeiss Meditec, Topcon, Inc.
Alcon Laboratories, Inc., Allergan, Inc, Pfizer, Inc., Merck, Inc, and Santen, Inc, provided the participants' glaucoma medications at no charge.
Supported by the National Eye Institute, National Institutes of Health, Bethesda, Maryland (grant nos.: P30EY022589 (L.M.Z.), U10EY14267 (L.M.Z.) EY019869 (L.M.Z.), EY021818 (F.A.M.), EY022039 (C.B.), EY08208 (F.A.M.), EY11008 (L.M.Z.), and EY13959) (C.A.G.); Eyesight Foundation of Alabama, Birmingham, AL (C.A.G.); the Edith C. Blum Research Fund of the New York Glaucoma Research Institute, New York, New York (J.M.L.); Japan Eye Bank Association, Tokyo, Japan (Overseas Research Grant [A.M.]); Research to Prevent Blindness, Inc., New York, New York (unrestricted grant) (R.N.W.).